

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Etrasimod for treating moderately to severely active ulcerative colitis

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes. Crohn's and Colitis UK stated "There is an advantage to a further treatment option which can be administered at home, which avoids the need for patients to take time off work or education and could potentially improve adherence.

The mode of administration could also benefit those with disabilities in terms of reducing the need to travel to hospital. Being able to take their treatment at home may also benefit cultures where it may be harder to speak openly about the condition or for those living in remote communities.

Certain medications attract prescription costs in England. These costs can be prohibitive to groups of patients, acting as a barrier to well-being and adherence".

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The comments on work, education, remote communities, and medication prescription costs are not specific to any particular protected characteristic group. Therefore, these issues are not expected to be relevant for committee discussion on equalities.

The mode of administration (potentially allowing administration at home and so helping people with disabilities, or people with cultural issues affecting open discussion of treatment and disease) should be considered

by committee. However, there are several oral treatments in the pathway already recommended for UC, including ozanimod and tofacitinib. It is not anticipated this intervention would offer benefits over and above treatments already recommended at this point in the pathway for UC.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

N/A

Approved by Associate Director (name): Janet Robertson

Date: 24/11/2022